PMID- 16603063
OWN - NLM
STAT- MEDLINE
DCOM- 20060801
LR  - 20231103
IS  - 1465-993X (Electronic)
IS  - 1465-9921 (Print)
IS  - 1465-9921 (Linking)
VI  - 7
IP  - 1
DP  - 2006 Apr 7
TI  - Health status measurement in COPD: the minimal clinically important difference of 
      the clinical COPD questionnaire.
PG  - 62
AB  - BACKGROUND: Patient-reported outcomes (PRO) questionnaires are being increasingly 
      used in COPD clinical studies. The challenge facing investigators is to determine 
      what change is significant, ie what is the minimal clinically important 
      difference (MCID). This study aimed to identify the MCID for the clinical COPD 
      questionnaire (CCQ) in terms of patient referencing, criterion referencing, and 
      by the standard error of measurement (SEM). METHODS: Patients were > or = 40 
      years of age, diagnosed with COPD, had a smoking history of >10 pack-years, and 
      were participating in a randomized, controlled clinical trial comparing 
      intravenous and oral prednisolone in patients admitted with an acute exacerbation 
      of COPD. The CCQ was completed on Days 1-7 and 42. A Global Rating of Change 
      (GRC) assessment was taken to establish the MCID by patient referencing. For 
      criterion referencing, health events during a period of 1 year after Day 42 were 
      included in this analysis. RESULTS: 210 patients were recruited, 168 completed 
      the CCQ questionnaire on Day 42. The MCID of the CCQ total score, as indicated by 
      patient referencing in terms of the GRC, was 0.44. The MCID of the CCQ in terms 
      of criterion referencing for the major outcomes was 0.39, and calculation of the 
      SEM resulted in a value of 0.21. CONCLUSION: This investigation, which is the 
      first to determine the MCID of a PRO questionnaire via more than one approach, 
      indicates that the MCID of the CCQ total score is 0.4.
FAU - Kocks, J W H
AU  - Kocks JW
AD  - Department of General Practice University Medical Center Groningen, The 
      Netherlands.
FAU - Tuinenga, M G
AU  - Tuinenga MG
FAU - Uil, S M
AU  - Uil SM
FAU - van den Berg, J W K
AU  - van den Berg JW
FAU - Stahl, E
AU  - Stahl E
FAU - van der Molen, T
AU  - van der Molen T
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20060407
PL  - England
TA  - Respir Res
JT  - Respiratory research
JID - 101090633
RN  - 0 (Anti-Inflammatory Agents)
RN  - 9PHQ9Y1OLM (Prednisolone)
SB  - IM
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Inflammatory Agents/administration & dosage/therapeutic use
MH  - Disease Progression
MH  - Endpoint Determination
MH  - *Health Status
MH  - Health Status Indicators
MH  - Humans
MH  - Injections, Intravenous
MH  - Middle Aged
MH  - Prednisolone/administration & dosage/therapeutic use
MH  - Pulmonary Disease, Chronic Obstructive/complications/drug 
      therapy/*physiopathology
MH  - Reference Values
MH  - *Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
PMC - PMC1508149
EDAT- 2006/04/11 09:00
MHDA- 2006/08/02 09:00
PMCR- 2006/04/07
CRDT- 2006/04/11 09:00
PHST- 2005/10/11 00:00 [received]
PHST- 2006/04/07 00:00 [accepted]
PHST- 2006/04/11 09:00 [pubmed]
PHST- 2006/08/02 09:00 [medline]
PHST- 2006/04/11 09:00 [entrez]
PHST- 2006/04/07 00:00 [pmc-release]
AID - 1465-9921-7-62 [pii]
AID - 10.1186/1465-9921-7-62 [doi]
PST - epublish
SO  - Respir Res. 2006 Apr 7;7(1):62. doi: 10.1186/1465-9921-7-62.